470 related articles for article (PubMed ID: 22952439)
1. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.
Ahuja SD; Ashkin D; Avendano M; Banerjee R; Bauer M; Bayona JN; Becerra MC; Benedetti A; Burgos M; Centis R; Chan ED; Chiang CY; Cox H; D'Ambrosio L; DeRiemer K; Dung NH; Enarson D; Falzon D; Flanagan K; Flood J; Garcia-Garcia ML; Gandhi N; Granich RM; Hollm-Delgado MG; Holtz TH; Iseman MD; Jarlsberg LG; Keshavjee S; Kim HR; Koh WJ; Lancaster J; Lange C; de Lange WC; Leimane V; Leung CC; Li J; Menzies D; Migliori GB; Mishustin SP; Mitnick CD; Narita M; O'Riordan P; Pai M; Palmero D; Park SK; Pasvol G; Peña J; Pérez-Guzmán C; Quelapio MI; Ponce-de-Leon A; Riekstina V; Robert J; Royce S; Schaaf HS; Seung KJ; Shah L; Shim TS; Shin SS; Shiraishi Y; Sifuentes-Osornio J; Sotgiu G; Strand MJ; Tabarsi P; Tupasi TE; van Altena R; Van der Walt M; Van der Werf TS; Vargas MH; Viiklepp P; Westenhouse J; Yew WW; Yim JJ;
PLoS Med; 2012; 9(8):e1001300. PubMed ID: 22952439
[TBL] [Abstract][Full Text] [Related]
2. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-Echevarría A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC;
PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958
[TBL] [Abstract][Full Text] [Related]
3. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
; Ahmad N; Ahuja SD; Akkerman OW; Alffenaar JC; Anderson LF; Baghaei P; Bang D; Barry PM; Bastos ML; Behera D; Benedetti A; Bisson GP; Boeree MJ; Bonnet M; Brode SK; Brust JCM; Cai Y; Caumes E; Cegielski JP; Centis R; Chan PC; Chan ED; Chang KC; Charles M; Cirule A; Dalcolmo MP; D'Ambrosio L; de Vries G; Dheda K; Esmail A; Flood J; Fox GJ; Fréchet-Jachym M; Fregona G; Gayoso R; Gegia M; Gler MT; Gu S; Guglielmetti L; Holtz TH; Hughes J; Isaakidis P; Jarlsberg L; Kempker RR; Keshavjee S; Khan FA; Kipiani M; Koenig SP; Koh WJ; Kritski A; Kuksa L; Kvasnovsky CL; Kwak N; Lan Z; Lange C; Laniado-Laborín R; Lee M; Leimane V; Leung CC; Leung EC; Li PZ; Lowenthal P; Maciel EL; Marks SM; Mase S; Mbuagbaw L; Migliori GB; Milanov V; Miller AC; Mitnick CD; Modongo C; Mohr E; Monedero I; Nahid P; Ndjeka N; O'Donnell MR; Padayatchi N; Palmero D; Pape JW; Podewils LJ; Reynolds I; Riekstina V; Robert J; Rodriguez M; Seaworth B; Seung KJ; Schnippel K; Shim TS; Singla R; Smith SE; Sotgiu G; Sukhbaatar G; Tabarsi P; Tiberi S; Trajman A; Trieu L; Udwadia ZF; van der Werf TS; Veziris N; Viiklepp P; Vilbrun SC; Walsh K; Westenhouse J; Yew WW; Yim JJ; Zetola NM; Zignol M; Menzies D
Lancet; 2018 Sep; 392(10150):821-834. PubMed ID: 30215381
[TBL] [Abstract][Full Text] [Related]
4. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.
Parmar MM; Sachdeva KS; Dewan PK; Rade K; Nair SA; Pant R; Khaparde SD
PLoS One; 2018; 13(4):e0193903. PubMed ID: 29641576
[TBL] [Abstract][Full Text] [Related]
5. Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis.
Lee H; Ahn S; Hwang NY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Kim CK; Koh WJ
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203478
[TBL] [Abstract][Full Text] [Related]
6. Social and health factors associated with adverse treatment outcomes among people with multidrug-resistant tuberculosis in Sierra Leone: a national, retrospective cohort study.
Kamara RF; Saunders MJ; Sahr F; Losa-Garcia JE; Foray L; Davies G; Wingfield T
Lancet Glob Health; 2022 Apr; 10(4):e543-e554. PubMed ID: 35303463
[TBL] [Abstract][Full Text] [Related]
7. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes.
Falzon D; Gandhi N; Migliori GB; Sotgiu G; Cox HS; Holtz TH; Hollm-Delgado MG; Keshavjee S; DeRiemer K; Centis R; D'Ambrosio L; Lange CG; Bauer M; Menzies D;
Eur Respir J; 2013 Jul; 42(1):156-68. PubMed ID: 23100499
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis.
Bastos ML; Cosme LB; Fregona G; do Prado TN; Bertolde AI; Zandonade E; Sanchez MN; Dalcolmo MP; Kritski A; Trajman A; Maciel ELN
BMC Infect Dis; 2017 Nov; 17(1):718. PubMed ID: 29137626
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.
Yew WW; Chan CK; Chau CH; Tam CM; Leung CC; Wong PC; Lee J
Chest; 2000 Mar; 117(3):744-51. PubMed ID: 10713001
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine.
Aibana O; Bachmaha M; Krasiuk V; Rybak N; Flanigan TP; Petrenko V; Murray MB
BMC Infect Dis; 2017 Feb; 17(1):129. PubMed ID: 28173763
[TBL] [Abstract][Full Text] [Related]
11. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F
Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.
Alene KA; Yi H; Viney K; McBryde ES; Yang K; Bai L; Gray DJ; Clements ACA; Xu Z
BMC Infect Dis; 2017 Aug; 17(1):573. PubMed ID: 28814276
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of risk factors associated with drug-resistant tuberculosis in Yemen: data from centres with high drug resistance.
Jaber AAS; Ibrahim B
BMC Infect Dis; 2019 May; 19(1):464. PubMed ID: 31126246
[TBL] [Abstract][Full Text] [Related]
14. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.
Fregonese F; Ahuja SD; Akkerman OW; Arakaki-Sanchez D; Ayakaka I; Baghaei P; Bang D; Bastos M; Benedetti A; Bonnet M; Cattamanchi A; Cegielski P; Chien JY; Cox H; Dedicoat M; Erkens C; Escalante P; Falzon D; Garcia-Prats AJ; Gegia M; Gillespie SH; Glynn JR; Goldberg S; Griffith D; Jacobson KR; Johnston JC; Jones-López EC; Khan A; Koh WJ; Kritski A; Lan ZY; Lee JH; Li PZ; Maciel EL; Galliez RM; Merle CSC; Munang M; Narendran G; Nguyen VN; Nunn A; Ohkado A; Park JS; Phillips PPJ; Ponnuraja C; Reves R; Romanowski K; Seung K; Schaaf HS; Skrahina A; Soolingen DV; Tabarsi P; Trajman A; Trieu L; Banurekha VV; Viiklepp P; Wang JY; Yoshiyama T; Menzies D
Lancet Respir Med; 2018 Apr; 6(4):265-275. PubMed ID: 29595509
[TBL] [Abstract][Full Text] [Related]
15. Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes.
Lee J; Lee CH; Kim DK; Yoon HI; Kim JY; Lee SM; Yang SC; Lee JH; Yoo CG; Lee CT; Chung HS; Kim YW; Han SK; Yim JJ
Korean J Intern Med; 2011 Jun; 26(2):153-9. PubMed ID: 21716591
[TBL] [Abstract][Full Text] [Related]
16. Aggressive Regimens Reduce Risk of Recurrence After Successful Treatment of MDR-TB.
Ahmad Khan F; Gelmanova IY; Franke MF; Atwood S; Zemlyanaya NA; Unakova IA; Andreev YG; Berezina VI; Pavlova VE; Shin SS; Yedilbayev AB; Becerra MC; Keshavjee S
Clin Infect Dis; 2016 Jul; 63(2):214-20. PubMed ID: 27161772
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses.
Ahmad Khan F; Salim MAH; du Cros P; Casas EC; Khamraev A; Sikhondze W; Benedetti A; Bastos M; Lan Z; Jaramillo E; Falzon D; Menzies D
Eur Respir J; 2017 Jul; 50(1):. PubMed ID: 28751411
[TBL] [Abstract][Full Text] [Related]
18. Treatment Outcomes of Multidrug-Resistant Tuberculosis in Taiwan: Tackling Loss to Follow-up.
Yu MC; Chiang CY; Lee JJ; Chien ST; Lin CJ; Lee SW; Lin CB; Yang WT; Wu YH; Huang YW
Clin Infect Dis; 2018 Jul; 67(2):202-210. PubMed ID: 29394358
[TBL] [Abstract][Full Text] [Related]
19. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003.
Brust JC; Gandhi NR; Carrara H; Osburn G; Padayatchi N
Int J Tuberc Lung Dis; 2010 Apr; 14(4):413-9. PubMed ID: 20202298
[TBL] [Abstract][Full Text] [Related]
20. Moxifloxacin Improves Treatment Outcomes in Patients with Ofloxacin-Resistant Multidrug-Resistant Tuberculosis.
Chien JY; Chien ST; Chiu WY; Yu CJ; Hsueh PR
Antimicrob Agents Chemother; 2016 Aug; 60(8):4708-16. PubMed ID: 27216062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
